A retrospective case series to determine safety and efficacy of canakinumab in patients with severe macrophage activation syndrome in systemic onset juvenile idiopathic arthritis, who failed the previous treatment
Latest Information Update: 22 Jun 2021
At a glance
- Drugs Canakinumab (Primary) ; Abatacept; Ciclosporin; Corticosteroids; Immunoglobulins; Methotrexate; Tocilizumab
- Indications Juvenile rheumatoid arthritis; Macrophage activation syndrome
- Focus Therapeutic Use
- 17 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism